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Background
Fluoropyrimidine-based chemotherapy plus the anti–vascular endothelial growth 
factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic 
colorectal cancer. We studied the effect of adding the anti–epidermal growth factor 
receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, 
and bevacizumab for metastatic colorectal cancer.
Methods
We randomly assigned 755 patients with previously untreated metastatic colorectal 
cancer to capecitabine, oxaliplatin, and bevacizumab (CB regimen, 378 patients) or 
the same regimen plus weekly cetuximab (CBC regimen, 377 patients). The primary 
end point was progression-free survival. The mutation status of the KRAS gene was 
evaluated as a predictor of outcome.
Results
The median progression-free survival was 10.7 months in the CB group and 9.4 in 
the CBC group (P = 0.01). Quality-of-life scores were lower in the CBC group. The 
overall survival and response rates did not differ significantly in the two groups. 
Treated patients in the CBC group had more grade 3 or 4 adverse events, which were 
attributed to cetuximab-related adverse cutaneous effects. Patients treated with cetux-
imab who had tumors bearing a mutated KRAS gene had significantly decreased 
progression-free survival as compared with cetuximab-treated patients with wild-
type–KRAS tumors or patients with mutated-KRAS tumors in the CB group.
Conclusions
The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted 
in significantly shorter progression-free survival and inferior quality of life. Muta-
tion status of the KRAS gene was a predictor of outcome in the cetuximab group. 
(ClinicalTrials.gov number, NCT00208546.)
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Fluoropyrimidines (e.g., fluorouracil and capecitabine), irinotecan, and oxalipla-tin are the standard cytotoxic drugs used 
in treating metastatic colorectal cancer.1,2 The 
combination of capecitabine and oxaliplatin is 
similar to the combination of f luorouracil and 
oxaliplatin in efficacy and safety.3,4 Bevacizumab, 
a humanized monoclonal antibody against vascu-
lar endothelial growth factor (VEGF),5-7 combined 
with fluoropyrimidine-based chemotherapy is 
now the standard first-line treatment for meta-
static co lo rec tal cancer. Cetuximab, a chimeric 
IgG1 monoclonal antibody against epidermal 
growth factor receptor (EGFR), has efficacy as 
monotherapy and in combination with irinotecan 
in irinotecan-resistant patients.8,9 We prospec-
tively evaluated the addition of cetuximab to 
capecitabine, oxaliplatin, and bevacizumab as 
first-line treatment in patients with metastatic 
colorectal cancer (the CAIRO2 trial).
Me thods
Patients
Eligible patients were older than 18 years of age, 
had histologically proved colon or rectal carci-
noma, metastatic disease not amenable to cura-
tive surgery, measurable tumor, no previous sys-
temic chemotherapy for metastatic disease, World 
Health Organization (WHO) performance status 
0 or 1, no adjuvant chemotherapy within 6 months 
before randomization, and adequate bone mar-
row, liver, and renal function. We excluded pa-
tients if they had higher than grade 1 sensory 
neuropathy, previous intolerance of adjuvant che-
motherapy, symptomatic central nervous system 
metastases, bleeding diathesis, coagulation dis-
orders, clinically significant cardiovascular dis-
ease, or other cancers within the previous 5 years, 
except for adequately treated squamous or basal-
cell carcinoma of the skin or carcinoma in situ of 
the cervix.
Study design
This open-label, randomized, phase 3 trial was 
conducted in 79 centers in the Netherlands. Eligi-
ble patients were randomly assigned at a 1:1 ratio 
to receive treatment with or without cetuximab. 
Randomization was performed centrally by a min-
imization technique with stratification according 
to serum lactate dehydrogenase level (normal or 
abnormal, according to the cutoff values of each 
individual center), previous adjuvant chemothera-
py (yes or no), number of affected organs (one or 
more than one), and treatment center. The study 
was approved by the Committee on Human-Relat-
ed Research Arnhem–Nijmegen and by the local 
institutional review boards. An independent data 
and safety monitoring committee evaluated all se-
rious adverse events. All patients provided written 
informed consent before study entry.
Bevacizumab was donated by Roche, and cetux-
imab was donated by Merck Serono. The spon-
sors of the study were informed of the results of 
the study but did not contribute to any phase of 
the study design; the collection, analysis, and in-
terpretation of the data; or the writing of the 
manuscript.
Treatment and Testing
Treatment for the capecitabine–bevacizumab (CB) 
group consisted of 1000 mg of capecitabine per 
square meter of body-surface area, given orally 
twice daily on days 1 to 14; 130 mg of oxaliplatin 
per square meter, given intravenously on day 1; 
and 7.5 mg of bevacizumab per kilogram of body 
weight, given intravenously on day 1. Treatment 
for the capecitabine–bevacizumab–cetuximab 
(CBC) group consisted of the same regimen of 
capecitabine, oxaliplatin, and bevacizumab plus 
400 mg of cetuximab per square meter, given 
intravenously on day 1 of the first treatment cy-
cle, followed by 250 mg of cetuximab per square 
meter given weekly thereafter. All treatment cycles 
were administered every 3 weeks. In both treat-
ment groups, oxaliplatin was administered for a 
maximum of six cycles to prevent serious periph-
eral sensory neurotoxicity, and from cycle 7 the 
dose of capecitabine was increased to 1250 mg 
per square meter. 
Adverse effects were graded according to the 
National Cancer Institute Common Toxicity Crite-
ria, version 3.0. Dose reductions because of adverse 
events were performed for each agent as speci-
fied in the study protocol. A cetuximab-related 
adverse cutaneous effect was defined as any ad-
verse cutaneous effect with the exception of hand–
foot syndrome. Central review was performed of 
the charts of all patients who died within 30 days 
after the last administration of the study drugs 
and whose death was accompanied by any event 
other than disease progression, regardless of the 
reported cause. The results of the central review 
were submitted to the independent data and safety 
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monitoring committee for final assessment. An 
interim analysis of safety in the first 400 pa-
tients has been published.10 
Tumor response was assessed by the local inves-
tigators every 9 weeks with the use of computed 
tomographic scans, according to the Response 
Evaluation Criteria in Solid Tumors (RECIST).11 
The overall response rate was defined as the rate 
of all responses, including complete and partial 
responses. Disease control was defined as com-
plete response, partial response, or stable disease 
as the best response. Treatment was continued 
until the occurrence of disease progression, death, 
or unacceptable adverse event, whichever came 
first. Patients whose treatment was discontinued 
for reasons other than disease progression were 
evaluated for a response every 3 months. The rela-
tive dose intensity was defined as the ratio of the 
dose administered to the planned dose. Quality of 
life was assessed by the European Organization 
for Research and Treatment of Cancer Quality of 
Life Questionnaire at baseline within 2 weeks 
before randomization and every 9 weeks there-
after until the end of the study treatment.
Formalin-fixed, paraffin-embedded tumor ma-
terial was collected from patients for whom re-
sected primary tumor tissue was available. DNA 
was extracted from tumor tissue for mutation 
analysis of the KRAS gene (see the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org).
EGFR expression was determined by immuno-
histochemical assay on tissue microarrays with the 
use of the EGFR pharmDx Kit (Dako) according 
to the manufacturer’s instructions. Powervision 
(Immunologic) was used as a visualization meth-
od. In accordance with the pharmDx Kit guide-
lines, tumors showing more than 1% membranous 
EGFR stained cells were considered positive.
Statistical Analysis
The primary end point was progression-free sur-
vival, which was defined as the interval from the 
date of randomization to the date of disease pro-
gression, death, or last follow-up, whichever oc-
curred first. It was estimated that with 540 events 
(progression or death), a two-sided log-rank test 
at a significance level of 5% would have a power 
of 80% to detect a difference in median progres-
sion-free survival of 11 to 14 months (hazard ratio, 
0.79). On the assumption of an accrual and follow-
up period of 36 months, we planned to include 
approximately 750 patients in the study. The sec-
ondary end points were overall survival, safety, 
response rate, quality of life, and the influence of 
KRAS mutational status and expression of EGFR 
in tumor samples on the outcome. Ineligible pa-
tients or patients who withdrew informed con-
sent were excluded from all analyses. Data from 
eligible patients were analyzed according to the 
intention-to-treat principle, and these patients re-
mained in follow-up until disease progression 
occurred. Data from patients who were alive with-
out recurrence at the time of analysis were cen-
sored. The progression-free and overall survival 
curves were estimated by the Kaplan–Meier meth-
od and compared by means of the log-rank test. 
We performed a multivariate analysis using a Cox 
proportional-hazards model with treatment group, 
serum lactate dehydrogenase level, number of af-
fected organs, and previous adjuvant chemother-
apy as covariables.
Patients who started treatment were evaluated 
for adverse events, and patients who completed at 
least three cycles were evaluated for response. 
The worst grade of adverse event was compared 
between the treatment groups with the use of the 
chi-square test. The correlation between cetuxi-
mab-related adverse cutaneous effects and sur-
vival was assessed in a landmark-type analysis. 
Patients who started treatment were grouped ac-
cording to the worst grade of cetuximab-related 
adverse cutaneous effect reported during the first 
six cycles. The Wilcoxon rank-sum test was used 
to detect statistically significant differences be-
tween the treatment groups in the change in the 
mean quality-of-life score. Patients who com-
pleted the quality-of-life questionnaire at baseline 
and at least once during treatment were evaluated. 
All analyses were performed with the use of SAS 
software, version 9.1.
R esult s
Patients
Between June 2005 and December 2006, 755 pa-
tients underwent randomization: 378 to receive 
treatment without cetuximab (CB group) and 377 
to receive treatment with cetuximab (CBC group). 
Nineteen patients (2.5%) were ineligible (Supple-
mentary Appendix). The study was completed ac-
cording to the protocol, and the estimated number 
of events occurred. The baseline characteristics of 
all 736 eligible patients (368 in each treatment 
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group) were well matched between the two 
groups except for sex (Table 1). The median dura-
tion of follow-up at the time of this analysis was 
23 months.
Treatment
Treatment was started in 732 eligible patients, 
366 in each group. The Supplementary Appendix 
gives the median and mean numbers of treatment 
cycles, the median duration of treatment, and the 
median relative dose intensity.
The reasons for discontinuation of treatment 
in the CB group (313 patients) and the CBC 
group (334 patients) were progression of disease 
(169 patients [54.0%] and 162 patients [48.5%], 
respectively; P = 0.16), adverse events (81 [25.9%] 
and 99 [29.6%], P = 0.28), resection of metastases 
(13 [4.2%] and 18 [5.4%], P = 0.46), and declining 
of treatment by the patient (19 [6.1%] and 25 
[7.5%], P = 0.48). All study drugs were discontin-
ued in 12 patients in the CBC group for adverse 
events that appeared to be related exclusively to 
cetuximab. A total of 345 of all 736 eligible pa-
tients (46.9%) received further systemic treat-
ment after disease progression: 168 in the CB 
group (45.7%) and 177 in the CBC group (48.1%). 
Of these patients, 48 received oxaliplatin (18 in 
the CB group and 30 in the CBC group), 278 re-
ceived irinotecan (144 and 134, respectively), and 
22 received cetuximab (15 and 7); cetuximab was 
usually administered in combination with irino-
tecan. 
Efficacy
The primary end point was reached in 293 pa-
tients in the CB group and 316 patients in the CBC 
group. The addition of cetuximab significantly 
decreased the median progression-free survival 
(10.7 months in the CB group and 9.4 months in 
the CBC group, P=0.01) (Table 2 and Fig. 1A). The 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
CB Group
(N = 368)
CBC Group
(N = 368) P Value
Age — yr 0.95
Median 62 62
Range 27–83 33–80
Sex — no. (%) 0.04
Male 205 (55.7) 233 (63.3)
Female 163 (44.3) 135 (36.7)
WHO performance status — no. (%) 0.09
0 219 (59.5) 240 (65.2)
1 149 (40.5) 126 (34.2)
No data 2 (0.5)
Serum lactate dehydrogenase level — no. (%) 0.82
Normal 210 (57.1) 207 (56.2)
Above normal 158 (42.9) 161 (43.8)
Previous adjuvant therapy — no. (%) 55 (14.9) 56 (15.2) 0.92
Site of primary tumor — no. (%) 0.50
Colon 164 (44.6) 172 (46.7)
Rectum 108 (29.3) 94 (25.5)
Rectosigmoid 96 (26.1) 102 (27.7)
No. of affected organs — no. (%) 0.77
1 167 (45.4) 163 (44.3)
>1 201 (54.6) 205 (55.7)
* CB denotes capecitabine, oxaliplatin, and bevacizumab, CBC capecitabine, oxaliplatin, and bevacizumab plus cetux-
imab, and WHO World Health Organization. Because of rounding, not all percentages total 100. 
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hazard ratio for disease progression or death in 
the CBC group was 1.22 (95% confidence interval, 
1.04 to 1.43). In a multivariate analysis, an elevated 
serum lactate dehydrogenase level (P<0.001) and 
treatment group (P = 0.03) correlated significantly 
with progression-free survival. The median overall 
survival was 20.3 months in the CB group and 19.4 
months in the CBC group (P = 0.16) (Table 2 and 
Fig. 1B). A total of 407 patients died, 193 in the CB 
group and 214 in the CBC group. The rate of death 
from any cause at 60 days was 1.9% in the CB 
group and 2.7% in the CBC group. The overall re-
sponse rate in the 649 patients who were evalu-
ated was 50.0% in the CB group and 52.7% in the 
CBC group (P = 0.49). Disease control was ob-
served in 94.0% of the patients in the CB group 
and 94.6% of those in the CBC group (P = 0.72).
Subgroup Analyses
The mutation status of the KRAS gene was evalu-
ated in 528 tumors (Table 3). Eight samples were 
excluded because of discordance in the results of 
the two test methods. An activating KRAS muta-
tion was found in 206 tumors (39.6%): 108 from 
patients in the CB group and 98 from patients in 
the CBC group. The baseline characteristics were 
well balanced between patients with wild-type–
KRAS tumors and those with mutated-KRAS tumors 
(data not shown). Cetuximab-treated patients with 
mutated-KRAS tumors had significantly shorter 
progression-free survival than cetuximab-treated 
patients with wild-type–KRAS tumors (8.1 vs. 10.5 
months, P = 0.04) (Fig. 2A). As compared with pa-
tients with mutated-KRAS tumors in the CB group, 
cetuximab-treated patients with mutated-KRAS 
tumors had significantly shorter progression-free 
survival (8.1 vs. 12.5 months, P = 0.003) and overall 
survival (17.2 vs. 24.9 months, P = 0.03). Among 
patients with wild-type–KRAS tumors, there was 
no significant difference in progression-free sur-
vival between the two treatment groups. Among 
patients treated with cetuximab, the response 
rate was significantly lower in those with KRAS 
mutations than in those with wild-type–KRAS tu-
Table 2. Efficacy of Study Treatment.*
Outcome
CB Group
(N = 368)
CBC Group
(N = 368) P Value
Progression-free survival (mo) 0.01
Median 10.7 9.4
95% CI 9.7–12.3 8.4–10.5
Overall survival (mo) 0.16
Median 20.3 19.4
95% CI 17.8–24.7 17.5–21.4
Response rate (%)† 50.0 52.7 0.49
Disease control rate (%)† 94.0 94.6 0.72
No. of treatment cycles 0.009
Median 10 9
Range 1–44 1–44
Duration of treatment (mo) <0.001
Median 7 6
Range 1–31 1–33
Primary reason for treatment discontinuation (%)
Disease progression 54.0 48.5 0.16
Adverse events 25.9 29.6 0.28
Other 20.1 21.9 0.59
60-Day mortality (%) 1.9 2.7 0.46
* CB denotes capecitabine, oxaliplatin, and bevacizumab, CBC capecitabine, oxaliplatin, and bevacizumab plus cetux-
imab, and CI confidence interval.
† A total of 649 patients (332 in the CB group and 317 in the CBC group) were evaluated for response.
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mors (45.9% vs. 61.4%, P = 0.03), whereas no sig-
nificant difference was observed in the CB group 
(59.2% vs. 50.0%, P = 0.16).
EGFR was evaluated in 496 tumors, of which 
315 (63.5%) tested positive. The baseline charac-
teristics were not significantly different between 
EGFR-positive and EGFR-negative patients (data 
not shown). Among EGFR-positive patients, the 
median progression-free survival was 12.2 months 
in the CB group and 9.8 months in the CBC group 
(P = 0.003). We did not observe a significant cor-
relation between KRAS mutation status or EGFR 
expression and the incidence of cetuximab-related 
adverse cutaneous effects (data not shown).
As compared with women in the CBC group, 
women who were assigned to the CB group had 
significantly better progression-free survival (12.5 
vs. 8.6 months, P<0.001) and overall survival (20.1 
vs. 18.8 months, P = 0.02). However, these differ-
ences were not observed in men. The distribution 
of baseline characteristics was similar in women 
and men. In a multivariate analysis, the interac-
tion between sex and treatment group was statis-
tically significant for progression-free survival 
(P = 0.005) but not for overall survival (P = 0.10).
The severity of cetuximab-related adverse cuta-
neous effects correlated significantly with progres-
sion-free survival (P<0.001) (Fig. 2B). The median 
progression-free survival in patients with grade 
0 or 1, patients with grade 2, and patients with 
grade 3 cetuximab-related adverse cutaneous ef-
fects was 7.8 months, 10.2 months, and 11.4 
months, respectively. The progression-free survival 
did not differ significantly between patients in the 
CB group and patients with grade 3 cetuximab-
related adverse cutaneous effects in the CBC 
group (P = 0.72).
Safety
Table 4 and the Supplementary Appendix list the 
most frequently observed grade 3 or 4 adverse 
events. The incidence of any grade 3 or 4 adverse 
event was 73.2% in the CB group and 81.7% in the 
CBC group (P = 0.006). When grade 3 cetuximab-
related adverse cutaneous effects were excluded 
from this analysis, the incidence was similar: 
73.2% in the CB group and 74.3% in the CBC 
group (P = 0.74). 
Quality of Life
A total of 532 patients (276 in the CB group and 
256 in the CBC group) were evaluated for quality 
of life. Overall quality of life and global health 
status were similar in the two groups at baseline; 
during treatment, both measures improved sig-
nificantly more in the CB group than in the CBC 
group (P = 0.007 and P = 0.03, respectively). The 
mean increase in global health status was 0.4 
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Figure 1. Kaplan–Meier Estimates of Progression-free and Overall Survival.
Panel A shows progression-free survival; the median was 9.4 months in the 
group receiving capecitabine, oxaliplatin, and bevacizumab plus cetuximab 
(CBC) and 10.7 months in the group receiving the sam  regimen without 
cetuximab (CB), corresponding to a hazard ratio of 1.22 (P = 0.01). Panel B 
shows overall survival; the median was 19.4 months in the CBC group and 
20.3 months in the CB group (P = 0.16; hazard ratio, 1.15).
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point in the CB group and 0.0 points in the CBC 
group (P = 0.007). There were no significant dif-
ferences between the treatment groups in the 
change from baseline in scores for pain, finan-
cial problems, and decrease in functioning (phys-
ical, emotional, cognitive, and social).
Discussion
In this randomized trial conducted in previously 
untreated patients with metastatic colorectal 
cancer, the addition of cetuximab to treatment 
with capecitabine, oxaliplatin, and bevacizumab 
resulted in a significant decrease in progression-
free survival and a poorer quality of life. The re-
duction in progression-free survival was unex-
pected, since preclinical as well as early clinical 
studies suggested a benefit from the combina-
tion of anti-VEGF and anti-EGFR antibodies.12-15 
An increase in adverse events is an unlikely cause 
of the reduction in progression-free survival, since 
such events were manageable and the percentage 
of patients who discontinued treatment because 
of adverse events was similar in the two treatment 
groups. A similar result with anti-EGFR therapy 
was observed in the Panitumumab Advanced 
Colo rectal Cancer Evaluation (PACCE) trial,16,17 
in which previously untreated patients with met-
astatic colorectal cancer were randomly assigned 
to fluorouracil, leucovorin, bevacizumab, and iri-
notecan or oxaliplatin, with or without panitu-
mumab, a human antibody against EGFR. The 
PACCE trial was prematurely discontinued be-
cause of decreased progression-free survival and 
increased adverse events in the panitumumab 
group, but the decrease in progression-free sur-
vival was observed only in patients who were treat-
ed with oxaliplatin. The Bowel Oncology with 
Cetuximab Antibody (BOND) 2 trial showed ef-
ficacy in treatment with irinotecan, bevacizumab, 
and cetuximab in patients with irinotecan-resis-
tant colorectal cancer,18 a result that suggested a 
higher response rate and longer progression-free 
survival than was found in a previous trial (BOND) 
of irinotecan and cetuximab in similar patients.9 
Preliminary results of chemotherapy with or with-
out cetuximab in the first-line treatment of meta-
static colorectal cancer indicate somewhat better 
progression-free survival with irinotecan than with 
oxaliplatin,19,20 but these comparisons should be 
interpreted with caution: whether cetuximab is 
more efficacious when given in combination with 
irinotecan than with oxaliplatin remains specu-
lative.
The results of our trial might be due to a 
negative interaction between cetuximab and be-
vacizumab. Hypertension, a common side effect 
of bevacizumab treatment, was recently shown to 
correlate with clinical outcome in patients with 
colorectal cancer.21 Our observation that hyper-
tension was less frequent in the CBC group sug-
gests decreased efficacy of bevacizumab when 
administered in combination with cetuximab. In 
contrast, preclinical studies have suggested a 
positive interaction between VEGF- and EGFR-
inhibiting agents.12-15 However, to our knowl-
edge, the combination of cetuximab and bevaci-
zumab has not been tested in this setting.
The severity of cetuximab-related adverse cuta-
neous effects correlated directly and significantly 
with progression-free survival, but the median 
progression-free survival among patients with the 
most severe cetuximab-related adverse cutane-
ous effects was not significantly better than that 
among patients treated without cetuximab.
Women treated with cetuximab had shorter 
progression-free survival than women treated 
Table 3. Association of the Mutation Status of the KRAS Gene with 
Progression-free Survival, Overall Survival, and Response Rate.*
Variable
Wild-Type 
KRAS
Mutated 
KRAS P Value
No. of patients 
CB group 156 108
CBC group 158 98
Median progression-free  
survival (mo)
CB group 10.6 12.5 0.80
CBC group 10.5 8.1 0.04
P value 0.30 0.003
Median overall survival (mo)
CB group 22.4 24.9 0.82
CBC group 21.8 17.2 0.06
P value 0.64 0.03
Response rate (%)
CB group 50.0 59.2 0.16
CBC group 61.4 45.9 0.03
P value 0.06 0.03
* CB denotes capecitabine, oxaliplatin, and bevacizumab, and CBC capecita-
bine, oxaliplatin, and bevacizumab plus cetuximab.
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Figure 2. Kaplan–Meier Estimates of Progression-free Survival According to KRAS Mutation Status and Cetuximab-
Related Adverse Cutaneous Effects.
Among patients in the group receiving capecitabine, oxaliplatin, and bevacizumab plus cetuximab (CBC), the medi-
an progression-free survival was significantly decreased when their tumor harbored a KRAS mutation (8.1 vs. 10.5 
months, P = 0.04) (Panel A). Among patients with mutated-KRAS tumors, the median progression-free survival was 
significantly decreased in the CBC group as compared with the group receiving capecitabine, oxaliplatin, and bevaci-
zumab (CB) (8.1 vs. 12.5 months, P = 0.003). In the CBC group, the median progression-free survival in treated pa-
tients with grade 0 or 1, treated patients with grade 2, and treated patients with grade 3 cetuximab-related adverse 
cutaneous effects was 7.8 months, 10.2 months, and 11.4 months, respectively (P<0.001) (Panel B). The difference 
between patients with grade 3 adverse cutaneous effects in the CBC group and patients in the CB group was not 
statistically significant (P=0.72).
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without cetuximab, but this difference was not 
found in men. Women also had a lower inci-
dence of grade 3 cetuximab-related adverse cuta-
neous effects, which might indicate a decreased 
efficacy of cetuximab in our study. Although the 
management of adverse cutaneous effects may 
be different in women than in men, with earlier 
discontinuation of cetuximab in women for cos-
metic reasons, this would not explain the poorer 
results in the CBC group.
The KRAS genotype affects the response to 
anti-EGFR treatment: patients with wild-type–
KRAS tumors have longer progression-free sur-
vival than those with mutated-KRAS tumors.22-26 
The results of our study also confirm the role of 
the mutation status of the KRAS gene in the re-
sponse to cetuximab when cetuximab is admin-
istered in combination with chemotherapy and 
bevacizumab as first-line treatment. We observed 
the worst result for progression-free survival in 
patients with mutated-KRAS tumors who were 
treated with cetuximab. A similar result was 
found in trials of chemotherapy with or without 
cetuximab as first-line treatment of metastatic 
colorectal cancer.25,26
Many targeted agents are available or under 
development for use in a wide range of tumors. 
The inhibition of a single signal-transduction 
pathway is unlikely to provide optimal results, 
and therefore a combination of agents appears 
to be a valid strategy. Our results, however, ar-
gue against the combined use of anti-VEGF and 
anti-EGFR monoclonal antibodies with chemo-
therapy in cases of metastatic colorectal cancer.
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Table 4. Serious Adverse Events.*
Event
CB Group
(N = 366)
CBC Group
(N = 366) P Value
number (percent)
Any grade 3 or 4 event 268 (73.2) 299 (81.7) 0.006
Adverse cutaneous effects
Any event 76 (20.8) 143 (39.1) <0.001
Acneiform rash 2 (0.5) 93 (25.4) <0.001
Hand–foot skin reaction 71 (19.4) 68 (18.6) 0.78
Diarrhea 70 (19.1) 95 (26.0) 0.03
Nausea 31 (8.5) 23 (6.3) 0.26
Vomiting 30 (8.2) 22 (6.0) 0.25
Fatigue 48 (13.1) 55 (15.0) 0.46
Sensory neuropathy 38 (10.4) 28 (7.7) 0.20
Infection 25 (6.8) 22 (6.0) 0.65
Neutropenic fever 5 (1.4) 3 (0.8) 0.48
Hypersensitivity reaction 15 (4.1) 18 (4.9) 0.59
Hypertension 54 (14.8) 34 (9.3) 0.02
Gastrointestinal perforation 1 (0.3) 6 (1.6) 0.06
Bleeding 6 (1.6) 2 (0.5) 0.16
Venous thromboembolic events 25 (6.8) 30 (8.2) 0.48
Arterial thromboembolic events 12 (3.3) 8 (2.2) 0.26
* CB denotes capecitabine, oxaliplatin, and bevacizumab, and CBC capecita-
bine, oxaliplatin, and bevacizumab plus cetuximab.
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